ASCO: Enzalutamide Monotherapy in Prostate Cancer Achieves ‘High Response Rate, Marked PSA Decline'

“Monotherapy with enzalutamide (Xtandi) achieved a “high PSA response rate and marked PSA decline” in patients with hormone-naïve prostate cancer after 6 months in a single-arm, multicenter phase II study, reported Matthew Raymond Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, Boston (abstract 5001). Efficacy was similar to castration, but in contrast with castration, bone mineral density (BMD) remained stable and metabolic variables, including fat body mass, lipid, and glycemic profiles, were not substantially impacted by enzalutamide over the 6-month study period.”